SCHEMBL6094543

SCHEMBL6094543

COc1ccc(CBr)cc1-c1cccs1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 5/20 0.47
ERN1 O75460 1/20 0.46
RPS6KB2 Q9UBS0 2/20 0.44
LMNA P02545 2/20 0.44
TSHR P16473 1/20 0.44
NPC1 O15118 5/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
RAB9A P51151 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
HTR1A P08908 2/20 0.41
HTR2C P28335 2/20 0.41
HTR2B P41595 2/20 0.41
HTR5A P47898 2/20 0.41
HTR6 P50406 2/20 0.41
TP53 P04637 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5990688 0.86 ERN1 (0.47) HTR7ERN1RPS6KB2LMNATSHR
SCHEMBL6094374 0.85 ERN1 (0.49) HTR7ERN1RPS6KB2LMNATSHR
SCHEMBL6094859 0.84 CYP1A2 (0.46) ERN1RPS6KB2LMNATSHRSMN1; SMN2
SCHEMBL6054842 0.80 MEN1 (0.49) HTR7ERN1RPS6KB2LMNATSHR
SCHEMBL28897591 0.79 PPARG (0.47) ERN1PPARG
SCHEMBL2780877 0.78 RPS6KB2 (0.56) ERN1RPS6KB2LMNATSHRNPC1
SCHEMBL11866560 0.78 MEN1 (0.66) ERN1RPS6KB2LMNANPC1MEN1
SCHEMBL14951060 0.78 ERN1 (0.50) ERN1RPS6KB2LMNANPC1MEN1
SCHEMBL6273269 0.76 ALDH1A1 (0.51) ERN1RPS6KB2LMNATSHRNPC1
SCHEMBL6769411 0.76 NPC1 (0.50) ERN1RPS6KB2LMNANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ATHEROGENICS, INC. 2006-03-23 US disclosed
WO-2006004903-A2 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF ATHEROGENICS, INC. (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ABCB11, CEL, CYP46A1 HTR7 953/4885ERN1 2367/4885RPS6KB2 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.